Systémová enzymoterapie pro odborníky

Oral Enzymes in Different Animal Models of Glomerulonephritis

Emancipator S.N.,¹ Chintalacharuvu S.R.,¹ Urankar Nagy N.,¹ Stauder G.²

¹Institute of Pathology and Radiology, Case Western Reserve University, Cleveland, OH, USA, ²Clinical Research, MUCOS Pharma GmbH, Geretsried, Germany.

Int J. Immunotherapy 1997, Vol. XIII, No. 3/4, pp. 97-103

SO 112 (19-04-2)- (5-07-2)

Summary

Systemic or oral proteolytic enzymes ameliorate any of several glomerulonephritides in mice, rats or rabbits. Recently, in rats with membranous nephropathy induced by cationized antigen, oral Phlogenzym^® therapy progressively diminished proteinuria and hyperlipidemia (ultimately by 50%) over a 2-week period, whereas untreated diseased controls showed stable and sustained proteinuria and hyperlipidemia. At sacrifice, the amount of glomerular immune deposits, assessed by semiquantitative immunofluorescence and quantitative electron microscopy were 45% of the amount in controls. Moreover, when this model was sustained for 7 months, glomerulosclerosis involved an average of approximately 80% of the glomeruli in untreated rats with nephrosis; whereas two different preparations of proteolytic enzymes, given intraperitoneally, had a significant sparing effect on glomeruli. Only 25% of the glomeruli from rats in either protease-treated group appeared sclerotic, as compared to 12% in nondiseased age-matched controls. We conclude that enzyme therapy diminishes the clinical signs and morphologic lesions of immune complex glomerulonephritis; reduces the immune deposits; and, prevents or retards the progression to end stage renal disease.


Úvod pro odborníky O firmě Kontakty Pomáháme druhým Poradna
Zánět a jeho ovlivnění SET Zvýšení využitelnosti antibiotik proteolytickými enzymy Angiologie, flebologie Diabetologie Gynekologie Chirurgie, traumatologie, ortopedie Imunologie Lymfologie ORL Pediatrie Revmatologie Sportovní medicína Stomatologie Urologie Literatura Časopisy s Impact faktorem Ostatní literatura SPC Wobenzym SPC Phlogenzym	Oral Enzymes in Different Animal Models of Glomerulonephritis Emancipator S.N.,¹ Chintalacharuvu S.R.,¹ Urankar Nagy N.,¹ Stauder G.² ¹Institute of Pathology and Radiology, Case Western Reserve University, Cleveland, OH, USA, ²Clinical Research, MUCOS Pharma GmbH, Geretsried, Germany. Int J. Immunotherapy 1997, Vol. XIII, No. 3/4, pp. 97-103 SO 112 (19-04-2)- (5-07-2) Summary Systemic or oral proteolytic enzymes ameliorate any of several glomerulonephritides in mice, rats or rabbits. Recently, in rats with membranous nephropathy induced by cationized antigen, oral Phlogenzym^® therapy progressively diminished proteinuria and hyperlipidemia (ultimately by 50%) over a 2-week period, whereas untreated diseased controls showed stable and sustained proteinuria and hyperlipidemia. At sacrifice, the amount of glomerular immune deposits, assessed by semiquantitative immunofluorescence and quantitative electron microscopy were 45% of the amount in controls. Moreover, when this model was sustained for 7 months, glomerulosclerosis involved an average of approximately 80% of the glomeruli in untreated rats with nephrosis; whereas two different preparations of proteolytic enzymes, given intraperitoneally, had a significant sparing effect on glomeruli. Only 25% of the glomeruli from rats in either protease-treated group appeared sclerotic, as compared to 12% in nondiseased age-matched controls. We conclude that enzyme therapy diminishes the clinical signs and morphologic lesions of immune complex glomerulonephritis; reduces the immune deposits; and, prevents or retards the progression to end stage renal disease.
	Lék pro vnitřní užití. Čtěte pečlivě příbalovou informaci. Inzertní stránky společnosti MUCOS Pharma CZ, s.r.o. - tel: (+420)-267 750 003